Brokerages Set Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Target Price at $106.08

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) has been assigned an average recommendation of “Hold” from the fifteen ratings firms that are covering the stock, MarketBeat reports. Nine research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokers that have covered the stock in the last year is $106.08.

A number of equities research analysts have weighed in on the company. Baird R W lowered Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 13th. Leerink Partnrs downgraded Intra-Cellular Therapies from a “strong-buy” rating to a “hold” rating in a report on Monday, January 13th. Needham & Company LLC reiterated a “hold” rating on shares of Intra-Cellular Therapies in a report on Friday, February 21st. Cantor Fitzgerald upgraded shares of Intra-Cellular Therapies from a “hold” rating to a “strong-buy” rating in a report on Tuesday, January 14th. Finally, Canaccord Genuity Group cut shares of Intra-Cellular Therapies from a “buy” rating to a “hold” rating and upped their price target for the stock from $119.00 to $132.00 in a research report on Friday, January 31st.

Institutional Trading of Intra-Cellular Therapies

Several hedge funds and other institutional investors have recently made changes to their positions in ITCI. MassMutual Private Wealth & Trust FSB increased its position in shares of Intra-Cellular Therapies by 124.3% in the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 133 shares during the period. M&T Bank Corp grew its position in shares of Intra-Cellular Therapies by 2.2% during the 4th quarter. M&T Bank Corp now owns 6,301 shares of the biopharmaceutical company’s stock valued at $526,000 after acquiring an additional 138 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Intra-Cellular Therapies by 1.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 8,951 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 141 shares in the last quarter. CIBC Asset Management Inc lifted its holdings in Intra-Cellular Therapies by 5.3% during the fourth quarter. CIBC Asset Management Inc now owns 2,956 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 150 shares in the last quarter. Finally, Pallas Capital Advisors LLC lifted its stake in Intra-Cellular Therapies by 6.4% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,182 shares of the biopharmaceutical company’s stock valued at $266,000 after buying an additional 192 shares in the last quarter. Hedge funds and other institutional investors own 92.33% of the company’s stock.

Intra-Cellular Therapies Price Performance

Shares of ITCI opened at $131.87 on Friday. The firm has a market capitalization of $14.05 billion, a price-to-earnings ratio of -151.57 and a beta of 0.69. Intra-Cellular Therapies has a 1-year low of $64.09 and a 1-year high of $131.98. The company has a 50-day moving average of $129.34 and a 200 day moving average of $100.60.

Intra-Cellular Therapies (NASDAQ:ITCI) last issued its earnings results on Friday, February 21st. The biopharmaceutical company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.08). The company had revenue of $199.22 million for the quarter, compared to analysts’ expectations of $205.08 million. Intra-Cellular Therapies had a negative return on equity of 9.93% and a negative net margin of 14.07%. On average, equities analysts anticipate that Intra-Cellular Therapies will post -0.64 earnings per share for the current fiscal year.

About Intra-Cellular Therapies

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.